The Novelty
Pelvic floor disorders are too often treated through surgery, implants, drugs, or long-term symptom management. AWCT is building a different path: an investigational acoustic pulse platform that applies proprietary, properly tuned pulses from outside the body to activate innate tissue repair. Born from UCSF research led by Dr. Tom Lue and backed by more than 20 years of NIH- and DOD-supported work, 65+ peer-reviewed publications, and a broad patent portfolio, AWCT is developing its first-generation device for women’s pelvic health — beginning with stress urinary incontinence — with a platform that may extend across viable tissues and disease models.
Pelvic floor disorders are too often treated through surgery, implants, drugs, or long-term symptom management. AWCT is building a different path: an investigational acoustic pulse platform that applies proprietary, properly tuned pulses from outside the body to activate innate tissue repair. Born from UCSF research led by Dr. Tom Lue and backed by more than 20 years of NIH- and DOD-supported work, 65+ peer-reviewed publications, and a broad patent portfolio, AWCT is developing its first-generation device for women’s pelvic health — beginning with stress urinary incontinence — with a platform that may extend across viable tissues and disease models.
The Challenge
AWCT is developing a novel acoustic pulse therapy platform for women’s pelvic health, beginning with stress urinary incontinence. Its investigational device has clinical evidence behind it, but moving toward commercialization requires translating a complex therapeutic technology, prior study data, device documentation, and FDA expectations into a complete, coherent 510(k) submission package.
AWCT is developing a novel acoustic pulse therapy platform for women’s pelvic health, beginning with stress urinary incontinence. Its investigational device has clinical evidence behind it, but moving toward commercialization requires translating a complex therapeutic technology, prior study data, device documentation, and FDA expectations into a complete, coherent 510(k) submission package.
The Solution
Panacea has begun supporting AWCT across its full 510(k) filing process, pairing senior FDA/CDRH medical device expertise with AI-native research, evidence synthesis, and submission drafting workflows. Our team is helping AWCT move from regulatory planning into execution: predicate research, evidence mapping, submission structure, documentation development, and the technical narrative needed to support FDA review.
Panacea has begun supporting AWCT across its full 510(k) filing process, pairing senior FDA/CDRH medical device expertise with AI-native research, evidence synthesis, and submission drafting workflows. Our team is helping AWCT move from regulatory planning into execution: predicate research, evidence mapping, submission structure, documentation development, and the technical narrative needed to support FDA review.